Embryo‐fetal safety evaluation of ondansetron in rats
Birth Defects Research · 2023
DOI: 10.1002/bdr2.2154 ↗At a glance
Journal article in Birth Defects Research, 2023. Written by Ana Carolina Casali Reis and 6 co-authors. Institution: Department of Structural and Functional Biology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista - UNESP, Botucatu, São Paulo, B…. Major MEDLINE topics: Antiemetics, Embryo, Mammalian, Ondansetron. Cited 1 times so far (Crossref); 41 references. Funded by: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (original language)
Background
Ondansetron is a 5HT3 receptor antagonist, used to mitigate the effects of nausea and vomiting after chemotherapy or surgery. Since nausea and vomiting are common experiences during the first trimester of pregnancy, this antiemetic has been the main drug used during this period.
Methods
To evaluate the effects of ondansetron on the embryo‐fetal development, which are still very contradictory, pregnant rats were exposed to therapeutic doses of ondansetron (1.7 or 2.5 mg/kg) daily, from gestational day (GD) 6 to 15.
Results
No clinical signs of toxicity were observed in dams during the treatment. Although the hemato‐biochemical parameters were similar among the groups, histological changes, as well as a reduction in the weight of kidney were found in the treated dams. After fetal examination, no visceral and skeletal abnormalities were observed in treated fetuses.
Conclusion
In conclusion, therapeutic doses of ondansetron have low teratogenic potential in rats. These data provide important information about the drug safety during pregnancy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Structural and Functional Biology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista - UNESP, Botucatu, São Paulo, Brazil.
- College of Health Science, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.
- Center of Toxicological Assistance (CEATOX), Institute of Biosciences of Botucatu, Universidade Estadual Paulista - Botucatu (UNESP), Botucatu, São Paulo, Brazil.
ORCID profiles: Arielle Cristina Arena
Funding
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Cite
APA
Reis, A. C. C., Jorge, B. C., da Silva Moreira, S., Stein, J., Perdão, C. B., de Matos Manoel, B., & Arena, A. C. (2023). Embryo‐fetal safety evaluation of ondansetron in rats. Birth Defects Research. https://doi.org/10.1002/bdr2.2154
Vancouver
Reis ACC, Jorge BC, da Silva Moreira S, Stein J, Perdão CB, de Matos Manoel B, et al. Embryo‐fetal safety evaluation of ondansetron in rats. Birth Defects Research. 2023. doi:10.1002/bdr2.2154
BibTeX
@article{Reis2023,
author = {Reis, Ana Carolina Casali and Jorge, Bárbara Campos and da Silva Moreira, Suyane and Stein, Júlia and Perdão, Carolina Barizan and de Matos Manoel, Beatriz and Arena, Arielle Cristina},
title = {Embryo‐fetal safety evaluation of ondansetron in rats},
journal = {Birth Defects Research},
year = {2023},
doi = {10.1002/bdr2.2154}
}
EUVIMED